Jasper Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Jasper Therapeutics, Inc. (JSPR), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are JSPR insiders buying or selling?
Jasper Therapeutics, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since August 2020, Trabud has recorded 36 Form 4 filings for JSPR: 10 buys ($11.5M) and 26 sells ($2.6M).
Source: SEC EDGAR Form 4
Key Statistics (August 2020 – Sep 24, 2025)
Total Form 4 filings
36
SEC EDGAR
Insider filers
12
Insider buys (10)
$11.5M
Insider sells (26)
$2.6M
Insider sentiment
Net buyingNet insider flow of $8.9M in net buying since August 2020.
Recent JSPR insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 24, 2025 | Thomas G Wiggans | Director | Purchase | 41.0K | $2.43 | $99.6K | SEC ↗ |
| Sep 24, 2025 | Svetlana Lucas | Director | Purchase | 20.0K | $2.43 | $48.6K | SEC ↗ |
| Sep 24, 2025 | MARTELL RON | President and CEO | Purchase | 41.0K | $2.43 | $99.6K | SEC ↗ |
| Sep 24, 2025 | Judith Anne Shizuru | Director | Purchase | 41.0K | $2.43 | $99.6K | SEC ↗ |
| Dec 13, 2024 | Jeetinder Singh Mahal | Chief Operating Officer | Sale | 900 | $22.11 | $19.9K | SEC ↗ |
| Sep 12, 2024 | Jeetinder Singh Mahal | Chief Operating Officer | Sale | 900 | $21.23 | $19.1K | SEC ↗ |
| Jun 13, 2024 | Jeetinder Singh Mahal | Chief Operating Officer | Sale | 900 | $24.16 | $21.7K | SEC ↗ |
| Mar 13, 2024 | Jeetinder Singh Mahal | Chief Operating Officer | Sale | 900 | $26.44 | $23.8K | SEC ↗ |
| Feb 12, 2024 | Carlyle Group Inc. | Other | Purchase | 190.0K | $12.95 | $2.5M | SEC ↗ |
| Nov 30, 2023 | Thomas G Wiggans | Director | Purchase | 10.0K | $0.65 | $6.5K | SEC ↗ |
| Nov 22, 2023 | Thomas G Wiggans | Director | Purchase | 10.0K | $0.64 | $6.4K | SEC ↗ |
| Nov 21, 2023 | Thomas G Wiggans | Director | Purchase | 30.0K | $0.61 | $18.2K | SEC ↗ |
| Oct 13, 2023 | William Lis | Director | Sale | 8.0K | $0.85 | $6.8K | SEC ↗ |
| Jun 14, 2023 | Jeetinder Singh Mahal | Chief Operating Officer, Chief Financial Officer and Corporate Secretary | Sale | 9.0K | $1.66 | $14.9K | SEC ↗ |
| Apr 14, 2023 | Anna Louise French | Director | Sale | 7.0K | $1.48 | $10.4K | SEC ↗ |
| Apr 14, 2023 | Kurt Von Emster | Director | Sale | 9.1K | $1.49 | $13.5K | SEC ↗ |
| Apr 14, 2023 | William Lis | Director | Sale | 8.5K | $1.44 | $12.2K | SEC ↗ |
| Apr 11, 2023 | Mark Mcdade | 10% Owner | Purchase | 2.7M | $1.50 | $4.0M | SEC ↗ |
| Jan 31, 2023 | Carlyle Group Inc. | 10% Owner | Purchase | 3.1M | $1.50 | $4.7M | SEC ↗ |
| Jan 26, 2023 | ROCHE HOLDING LTD | 10% Owner | Sale | 75.0K | $1.89 | $141.8K | SEC ↗ |
| Jun 28, 2022 | William Lis | Director | Sale | 49.5K | $2.05 | $101.4K | SEC ↗ |
| Apr 23, 2021 | GLAZER CAPITAL, LLC | 10% Owner | Sale | 152.9K | $9.92 | $1.5M | SEC ↗ |
| Apr 21, 2021 | GLAZER CAPITAL, LLC | 10% Owner | Sale | 2.1K | $9.97 | $20.5K | SEC ↗ |
| Feb 22, 2021 | GLAZER CAPITAL, LLC | 10% Owner | Sale | 12.8K | $10.46 | $134.0K | SEC ↗ |
| Feb 9, 2021 | GLAZER CAPITAL, LLC | 10% Owner | Sale | 212 | $10.40 | $2.2K | SEC ↗ |
Showing the 25 most recent of 36 Form 4 filings for Jasper Therapeutics, Inc..
Most active JSPR insiders
- GLAZER CAPITAL, LLC15 filings
- Jeetinder Singh Mahal5 filings
- Thomas G Wiggans4 filings
- William Lis3 filings
- Carlyle Group Inc.2 filings
Ask anything about JSPR insider activity
Use Trabud's AI agent to query Jasper Therapeutics, Inc.'s Form 4 history in plain English — "Show me JSPR CEO purchases this year" or compare it against any other ticker.
Open the AI agentJSPR insider trading FAQ
Are Jasper Therapeutics, Inc. insiders buying or selling?
Jasper Therapeutics, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since August 2020, Trabud has recorded 36 Form 4 filings for JSPR: 10 buys ($11.5M) and 26 sells ($2.6M). Over the full record that is net buying of $8.9M.
How many insiders trade JSPR stock?
12 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Jasper Therapeutics, Inc.. The most recent filing was accepted on Sep 24, 2025.
Where does Trabud get JSPR insider trading data?
All JSPR insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.